Semaglutide, a GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, is typically supplied in pre-filled pens that display doses in milligrams
MMRM, mixed model for repeated measures
Physical therapy, heat therapy, gentle stretching, and low-impact exercise help manage musculoskeletal pain while supporting weight loss goals
Bayandor was having difficulty shedding the tough-to-lose baby weight and after talking to her doctor she started taking Wegovy in August 2021
Sources Food and Drug Administration (FDA): FDA Approves New Medication for Chronic Weight Management Molecular Metabolism Journal: Glucagon-like peptide 1 (GLP-1) American Gastroenterological Association (AGA): Biology of Incretins: GLP-1 and GIP Columbia Surgery: The Ozempic Effect: Everything You Need to Know About Medical Weight Loss Eli Lilly: Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies American Diabetes Association (ADA): Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes Important Medical Information and Disclaimers Important Current Status Update : As of March 19, 2025, the FDA has ended enforcement discretion for compounded tirzepatide
- If you have any questions or concerns about using Wegovy, consult your healthcare provider